Medicines and IP: Balancing Innovation and Access

Judiciary: House Committee · June 4, 2026

0:00/2:12

2:12:21

0:00

30:00

1:00:00

1:30:00

2:10:00

Chair opens hearing, scope and concerns

Presentation

21:35 → 28:41(7m 6s)

Chairman Issa opened the subcommittee, framed the hearing as focused on patents (not FDA or reimbursement), and said the panel will examine whether practices labeled 'patent thickets' are preventing competition; he flagged proposals to restrict exports and raised recent PTAB staffing changes as a concern for patent quality.

Keywords:

Speakers:

A House Judiciary subcommittee hearing examined patent 'thickets,' the Ethic Act and a separate skinny-label bill as lawmakers and witnesses debated how to balance incentives for pharmaceutical innovation with faster access to generics and biosimilars; a Supreme Court decision on skinny labels was issued the same morning and shaped the discussion.

AI-Generated Content

The text on this page is AI generated. Summaries, highlights, analysis, and video transcripts are all produced from the original source material.

AI can make mistakes, so if you spot one, and we will fix it for everyone.

Note: the source content is unaltered by us. Any content source we link to, be it a video, an audio recording, or a document, is presented exactly as its publisher released it. That publisher is usually a government body, sometimes an individual official or another organisation.

No transcript available.